RECOMBINANT LEUKOCYTE ALPHA INTERFERON IN NON-HODGKIN'S LYMPHOMA PATIENTS

生物反应调节剂计划中的先前研究， 在其它地方已经证明了重组α-葡聚糖的显著活性， 干扰素治疗复发性组织学良好的非何杰金氏病患者 弥漫性低分化淋巴瘤。 然而，大多数进入本试验的患者需要减少剂量 因为毒性过大 与初始研究同时进行的研究 其他机构的淋巴瘤研究表明， 极低剂量重组α干扰素治疗毛细胞癌 白血病，另一种慢性B细胞肿瘤 当前的目的 试验旨在确定具有良好组织学、非霍奇金淋巴瘤 淋巴瘤会对低剂量的干扰素产生反应， 对毛细胞白血病患者有效。 的第二个目的 试验是为了进一步评估高剂量重组α 干扰素治疗弥漫性低分化淋巴瘤 这些患者中只有少数在最初的试验中接受了治疗。 试验的第三个目的是试图确定低剂量 重组α-干扰素对患有 最近描述的T γ淋巴增生性疾病，一种T 在许多方面类似于毛细胞白血病的细胞。

Previous investigations in the Biological Response Modifiers Program and elsewhere have demonstrated significant activity of recombinant alpha interferon in patients with relapsed favorable histology non-Hodgkin's lymphoma and in some patients with diffuse poorly differentiated lymphoma. Most patients entered on this trial, however, require dose reductions because of excessive toxicity. Studies done concurrently with the initial lymphoma studies at other institutions demonstrate significant activity of very low doses of recombinant alpha interferon in patients with hairy cell leukemia, another chronic B-cell neoplasm. The purpose of the current trial was to determine if patients with favorable histology, non-Hodgkin's lymphoma would respond to the lower doses of interferon found to be very effective in patients with hairy cell leukemia. A second objective of the trial was to further evaluate the efficacy of high dose recombinant alpha interferon in patients with diffuse poorly differentiated lymphoma since only small numbers of these patients had been treated in the intial trial. The third objective of the trial was to attempt to determine if low doses of recombinant alpha interferon would be effective in patients with the recently described T gamma lymphoproliferative disorder, a disorder of T cells that resembles in many regards hairy cell leukemia.